Aro Biotherapeutics opens enrollment of Phase 1b trial of ABX1100 in patients with late-onset Pompe disease
- Aro Biotherapeutics has initiated a Phase 1b trial for ABX1100, targeting late-onset Pompe disease (LOPD).
- ABX1100 uses siRNA therapy to inhibit GYS1 enzyme production, aiming to reduce glycogen buildup in muscles.
- The trial will assess the safety and bioactivity of ABX1100 in adults with LOPD.
- ABX1100 has shown promising results in preclinical studies and has received Orphan Drug Designation from the FDA.
Read more
Medidata and Cogstate form strategic partnership to enhance CNS clinical trials
- Medidata and Cogstate partner to improve clinical trials for CNS diseases using eCOA and AI.
- The collaboration offers a unified platform for CNS assessment, enhancing data quality and efficiency.
- Biopharmaceutical customers benefit from a single device for comprehensive patient outcome assessments.
- The partnership aims to deliver precise data for better clinical trial decision-making and patient outcomes.
Read more
Cognito Therapeutics announces Spectris treatment reduces Alzheimer’s dependence score
- Spectris treatment showed a 56.4% reduction in Alzheimer’s Disease Dependence Score in the Phase 2 OVERTURE study.
- The study involved 44 participants, with significant results observed over 18 months (p=0.0396).
- No serious treatment-related adverse events were reported, indicating a strong safety profile.
- Cognito is enrolling patients for the Phase 3 HOPE study, focusing on diverse participant demographics.
Read more
INBRAIN Neuroelectronics raises $50M series B to advance graphene-based brain-computer interface technology
- INBRAIN Neuroelectronics secured $50 million in Series B funding led by imec.xpand, with participation from new and existing investors.
- The funding will accelerate the development of INBRAIN's graphene-based BCI-Tx platform, supporting clinical trials and team expansion.
- INBRAIN's technology uses graphene to decode and modulate neural signals, offering precision in treating neurological diseases.
- A collaboration with imec will help scale graphene interfaces commercially, with ongoing trials evaluating safety in brain cancer patients.
Read more
